title: Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?
authors.affiliation: Larry Hillblom Islet Research Center at David Geffen School of Medicine, UCLA, Los Angeles, CA 90024-2852, USA. pbutler@mednet.ucla.edu
authors.forename: P C
authors.initials: PC
authors.lastname: Butler
authors.forename: A V
authors.initials: AV
authors.lastname: Matveyenko
authors.forename: S
authors.initials: S
authors.lastname: Dry
authors.forename: A
authors.initials: A
authors.lastname: Bhushan
authors.forename: R
authors.initials: R
authors.lastname: Elashoff
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D052216:Glucagon-Like Peptide 1 / Q000627:therapeutic use*; D006801:Humans; D006965:Hyperplasia / Q000188:drug therapy; D046790:Pancreas, Exocrine / Q000187:drug effects*; D010183:Pancreatic Ducts / Q000187:drug effects / Q000473:pathology; D010195:Pancreatitis / Q000188:drug therapy*; D050500:Pancreatitis, Chronic / Q000188:drug therapy / Q000503:physiopathology; D051381:Rats; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D052216:Glucagon-Like Peptide 1